Findings

What do systematic reviews say?

1,549 questions · 1,604 findings · 181 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 258 · 16.1%GRADE not reported 69 · 4.3%Very low 337 · 21%Low 406 · 25.3%Moderate 410 · 25.6%High 124 · 7.7%

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐5 mAb (mepolizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.73 [0.36, 1.47]
2 studies · 135 participants
Low

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Moderate

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Disease severity, as measured by validated, patient‐reported symptom score · patients with chronic rhinosinusitis with nasal polyps

The review found no eligible studies for this question.

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Serious adverse events · patients with chronic rhinosinusitis with nasal polyps

It is very uncertain whether anti‐IgE mAb (omalizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.32 [0.05, 2]
5 studies · 329 participants
Very low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Disease severity ‐ VAS (range 0 to 10, lower = better) · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
Moderate

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an improvement in SNOT‐22 score of ≥ 8.9 points · patients with chronic rhinosinusitis with nasal polyps

Anti‐IgE mAb (omalizumab) may leads to higher avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an… compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 5.6 [1.99, 15.76]
2 studies · 265 participants
Low

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Extent of disease ‐ endoscopic score · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 312 participants
Low

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Extent of disease ‐ CT scan (lower score = better) · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 47 participants
Very low

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 38 participants
Very low

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Adverse events ‐ nasopharyngitis, including sore throat · patients with chronic rhinosinusitis with nasal polyps

Anti‐IgE mAb (omalizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.71 [0.29, 1.73]
5 studies · 329 participants
Low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐4Rα mAb (dupilumab) may leads to lower serious adverse events compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.47 [0.29, 0.76]
3 studies · 782 participants
Low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Avoidance of surgery ‐ number of patients who had surgery as rescue treatment · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐4Rα mAb (dupilumab) probably leads to lower avoidance of surgery ‐ number of patients who had surgery as rescue… compared with placebo (on top of topical steroids) (moderate certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.17 [0.05, 0.52]
2 studies · 725 participants
Moderate

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Extent of disease ‐ endoscopic score · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
Moderate

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Extent of disease ‐ CT scan (lower score = better) · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
High

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 766 participants
Moderate

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐4Rα mAb (dupilumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat (longest… compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.95 [0.72, 1.25]
3 studies · 783 participants
Low

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low

Levamisole vs steroids or placebo or both, or no treatment

Relapse during treatment (4 to 12 months) · SSNS in children

Levamisole may leads to lower relapse during treatment (4 to 12 months) compared with steroids or placebo or both, or no treatment (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.52 [0.33, 0.82]
8 studies · 474 participants
Low

Levamisole vs steroids or placebo or both, or no treatment

Clinical relapse · SSNS in children

Levamisole may leads to lower relapse at 6 to 12 months compared with steroids or placebo or both, or no treatment (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.65 [0.48, 0.88]
8 studies · 462 participants
Low